AFAna Flávia dos Santos Fuzaro

Ana Flávia dos Santos Fuzaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Flávia dos Santos Fuzaro has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Formulation of Tryptanthrin incorporated in Pluronic-based copolymers aiming biomedical purposes

    by Bruno Vilsinski, Ana dos Santos Fuzaro, Maria de Paula Rodrigues, Thais de Souza Oliveira, Frederico Silva, Jacy Gameiro, Richard Grazul, Mauro de Almeida, Wilson Braz, Caroline Raquel Bender, et al.

    The hydrophobicity of natural products is a challenge in medicinal chemistry, where there is a high demand for improving bioavailability to enable the clinical use of these compounds. Thus, this study investigated the potential of Pluronic-F127 and Pluronic-P123 as carrier systems for tryptanthrin (TRYP), a natural product with various biological properties, particularly its anticancer activity. Our research group synthesized TRYP and micelles using the solid dispersion method, which were characterized by UV-VIS, FTIR, DLS, TGA, and DSC techniques. The encapsulation efficiency of the formulated TRYP/F-127 and TRYP/P-123 was 76.10±1.20 and 75.36 ± 2.20%, respectively. The nanostructured system was effective in promoting the solubilization of TRYP in an aqueous medium. In vitro cellular viability was assessed against the MCF-7 cell line, showing that both formulations increased cytotoxicity against the tested tumor cells and are promising for bioapplication.

  • Open Access

    Natural Products and Synthetic Derivatives as Promising Candidates Against Neglected Tropical Diseases

    by Ana Flávia dos Santos Fuzaro, Carolina Sousa Ponciano, José C. Barros, Richard M. Grazul, Mauro Vieira de Almeida, Eloah Pereira Ávila

    Neglected Tropical Diseases (NTD) are a group of endemic diseases that cause up to one million deaths annually. Leishmaniasis and Chagas Disease are classified as NTD whose current treatments are of limited access. There is an urgent need to develop new agents to combat or alleviate the symptoms of these pathologies. The present work highlights the activities of several natural products and their derivatives which have been tested against the causative parasites of both diseases. The activities of natural products illustrate their potential to assist in the combat against NTD. Research in this area could provide an opportunity to advance medical research and to provide treatments to low- and middle-income countries.